Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma [PDF]
Scientific Reports, 2022 Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) might be involved in the activation of important pathways related to tumor immune escape, along with programmed death-ligand 1 (PD-L1).
Ju Zhao +12 more
doaj +2 more sources
Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. [PDF]
Cancer Res Commun, 2023 Siglec-15 (Sig15) has been implicated as an immune checkpoint expressed in solid tumor-infiltrating macrophages and is being targeted in clinical trials with mAbs to normalize the tumor immune microenvironment and stimulate antitumor immunity.
Pillsbury CE +18 more
europepmc +2 more sources
Siglec-15-induced autophagy promotes invasion and metastasis of human osteosarcoma cells by activating the epithelial–mesenchymal transition and Beclin-1/ATG14 pathway [PDF]
Cell & Bioscience, 2022 Background Pulmonary metastasis is the main cause of poor prognosis in osteosarcoma. Sialic acid-bound immunoglobulin lectin 15 (Siglec-15) has been demonstrated to be obviously correlated with pulmonary metastasis in osteosarcoma patients.
Bingxin Zheng +10 more
doaj +2 more sources
Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma. [PDF]
Virchows Arch, 2023 Core needle biopsies (CNB) are widely used to diagnose breast cancer, but the procedure is invasive and thus, it changes the tumor microenvironment. The purpose of this study is to see how the expression of three potentially anti-inflammatory molecules ...
Mutka M +4 more
europepmc +2 more sources
Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions. [PDF]
J Immunother, 2023 Siglec-15, an inhibitory immune checkpoint, is an emerging target in cancer immunotherapy. Blocking the function of Siglec-15 is an excellent strategy for cancer treatment and antibody blockade has been used to target Siglec-15.
Ding H +7 more
europepmc +2 more sources
OncoImmunology, 2020 Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is considered a novel anti-tumor target comparable to programmed cell death 1 ligand 1(PD-L1). However, little is known about Siglec-15.
Baihui Li +8 more
doaj +2 more sources
Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy. [PDF]
Clin Cancer Res, 2021 Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to treat cancer. The explanation underlying the success of these agents may be the selective expression of PD-L1 with dominant immune-suppressive activities in the tumor ...
Sun J, Lu Q, Sanmamed MF, Wang J.
europepmc +2 more sources
Development of an immunohistochemical assay for Siglec-15. [PDF]
Lab Invest, 2022 Siglec-15, a member of sialic-acid binding immunoglobulin type lectins, is normally expressed by myeloid cells and upregulated in some human cancers and represents a promising new target for immunotherapy.
Shafi S +17 more
europepmc +4 more sources
A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mφ polarization in TME
Pharmacological Research, 2022 Background: Siglec-15 (S15) is a type-I transmembrane protein and is considered a new candidate of immune checkpoint inhibitor for cancer immunotherapy.
Xuejun Xiao +14 more
doaj +2 more sources
Siglec-15 promotes progression of clear renal cell carcinoma [PDF]
Chinese Medical Journal, 2021 Wen-Bo Yang +5 more
doaj +2 more sources